108 related articles for article (PubMed ID: 10362532)
61. Human TAF-Iα promotes oncogenic transformation via enhancement of cell proliferation and suppression of apoptosis.
Nenasheva VV; Makarova IV; Stepanenko EA; Antonov SA; Novosadova EV; Narsullaeva AR; Kozikova LV; Polteva EA; Sleptsova LA; Shcherbatova NA; Khaidarova NV; Andreeva LE; Tarantul VZ
In Vitro Cell Dev Biol Anim; 2021 May; 57(5):531-538. PubMed ID: 34021475
[TBL] [Abstract][Full Text] [Related]
62. Distribution of SET/I2PP2A protein in gastrointestinal tissues.
Umata K; Sakai Y; Ikeda S; Tsuji S; Kawasaki H; Ohama T; Sato K
PLoS One; 2019; 14(9):e0222845. PubMed ID: 31557212
[TBL] [Abstract][Full Text] [Related]
63. SET binding to Sgo1 inhibits Sgo1-cohesin interactions and promotes chromosome segregation.
Qu Q; Zhang Q; Yang L; Chen Y; Liu H
J Cell Biol; 2019 Aug; 218(8):2514-2528. PubMed ID: 31227592
[TBL] [Abstract][Full Text] [Related]
64. The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction.
De Palma RM; Parnham SR; Li Y; Oaks JJ; Peterson YK; Szulc ZM; Roth BM; Xing Y; Ogretmen B
FASEB J; 2019 Jun; 33(6):7647-7666. PubMed ID: 30917007
[TBL] [Abstract][Full Text] [Related]
65. SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.
Brander DM; Friedman DR; Volkheimer AD; Christensen DJ; Rassenti LZ; Kipps TJ; Guadalupe E; Chen Y; Zhang D; Wang X; Davis C; Owzar K; Weinberg JB
Br J Haematol; 2019 Feb; 184(4):605-615. PubMed ID: 30443898
[TBL] [Abstract][Full Text] [Related]
66. SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment.
Huang YH; Chu PY; Chen JL; Huang CT; Lee CH; Lau KY; Wang WL; Wang YL; Lien PJ; Tseng LM; Liu CY
J Clin Med; 2018 Aug; 7(9):. PubMed ID: 30154367
[TBL] [Abstract][Full Text] [Related]
67. The role of SET/I2PP2A in canine mammary tumors.
Kake S; Tsuji S; Enjoji S; Hanasaki S; Hayase H; Yabe R; Tanaka Y; Nakagawa T; Liu HP; Chang SC; Usui T; Ohama T; Sato K
Sci Rep; 2017 Jun; 7(1):4279. PubMed ID: 28655918
[TBL] [Abstract][Full Text] [Related]
68. All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.
Sangodkar J; Farrington CC; McClinch K; Galsky MD; Kastrinsky DB; Narla G
FEBS J; 2016 Mar; 283(6):1004-24. PubMed ID: 26507691
[TBL] [Abstract][Full Text] [Related]
69. The N-terminal Set-β Protein Isoform Induces Neuronal Death.
Trakhtenberg EF; Morkin MI; Patel KH; Fernandez SG; Sang A; Shaw P; Liu X; Wang Y; Mlacker GM; Gao H; Velmeshev D; Dombrowski SM; Vitek MP; Goldberg JL
J Biol Chem; 2015 May; 290(21):13417-26. PubMed ID: 25833944
[TBL] [Abstract][Full Text] [Related]
70. Regulation of PP2A by Sphingolipid Metabolism and Signaling.
Oaks J; Ogretmen B
Front Oncol; 2014; 4():388. PubMed ID: 25642418
[TBL] [Abstract][Full Text] [Related]
71. The Basic Biology of PP2A in Hematologic Cells and Malignancies.
Haesen D; Sents W; Lemaire K; Hoorne Y; Janssens V
Front Oncol; 2014; 4():347. PubMed ID: 25566494
[TBL] [Abstract][Full Text] [Related]
72. Upregulation of SET expression by BACE1 and its implications in Down syndrome.
Zhang X; Wu Y; Duan X; Chen W; Zou H; Zhang M; Zhang S; Cai F; Song W
Mol Neurobiol; 2015 Apr; 51(2):781-90. PubMed ID: 24935721
[TBL] [Abstract][Full Text] [Related]
73. Characterization of SET/I2PP2A isoforms in dogs.
Yabe R; Fujiwara N; Mizuno T; Usui T; Ohama T; Sato K
J Vet Med Sci; 2014 Sep; 76(9):1235-40. PubMed ID: 24897959
[TBL] [Abstract][Full Text] [Related]
74. Regulating Set-β's Subcellular Localization Toggles Its Function between Inhibiting and Promoting Axon Growth and Regeneration.
Trakhtenberg EF; Wang Y; Morkin MI; Fernandez SG; Mlacker GM; Shechter JM; Liu X; Patel KH; Lapins A; Yang S; Dombrowski SM; Goldberg JL
J Neurosci; 2014 May; 34(21):7361-74. PubMed ID: 24849368
[TBL] [Abstract][Full Text] [Related]
75. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.
Pippa R; Dominguez A; Christensen DJ; Moreno-Miralles I; Blanco-Prieto MJ; Vitek MP; Odero MD
Leukemia; 2014 Sep; 28(9):1915-8. PubMed ID: 24781014
[No Abstract] [Full Text] [Related]
76. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Oaks JJ; Santhanam R; Walker CJ; Roof S; Harb JG; Ferenchak G; Eisfeld AK; Van Brocklyn JR; Briesewitz R; Saddoughi SA; Nagata K; Bittman R; Caligiuri MA; Abdel-Wahab O; Levine R; Arlinghaus RB; Quintas-Cardama A; Goldman JM; Apperley J; Reid A; Milojkovic D; Ziolo MT; Marcucci G; Ogretmen B; Neviani P; Perrotti D
Blood; 2013 Sep; 122(11):1923-34. PubMed ID: 23926298
[TBL] [Abstract][Full Text] [Related]
77. Phosphorylation of SET protein at Ser171 by protein kinase D2 diminishes its inhibitory effect on protein phosphatase 2A.
Irie A; Harada K; Araki N; Nishimura Y
PLoS One; 2012; 7(12):e51242. PubMed ID: 23251465
[TBL] [Abstract][Full Text] [Related]
78. Modulation of signaling pathways by RNA virus capsid proteins.
Urbanowski MD; Ilkow CS; Hobman TC
Cell Signal; 2008 Jul; 20(7):1227-36. PubMed ID: 18258415
[TBL] [Abstract][Full Text] [Related]
79. Activated glucocorticoid receptor interacts with the INHAT component Set/TAF-Ibeta and releases it from a glucocorticoid-responsive gene promoter, relieving repression: implications for the pathogenesis of glucocorticoid resistance in acute undifferentiated leukemia with Set-Can translocation.
Ichijo T; Chrousos GP; Kino T
Mol Cell Endocrinol; 2008 Feb; 283(1-2):19-31. PubMed ID: 18096310
[TBL] [Abstract][Full Text] [Related]
80. Histone acetylation-independent transcription stimulation by a histone chaperone.
Kato K; Miyaji-Yamaguchi M; Okuwaki M; Nagata K
Nucleic Acids Res; 2007; 35(3):705-15. PubMed ID: 17179179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
